Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
PAPZIMEOS Q2 revenue more than doubled to $53.1 million, EPS of $0.05 beat an expected loss, and FDA exclusivity runs through 2032. Shares gained about 34% over 21 sessions, with $7.44 the near-term breakout level.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profit rebound ⢠Cash conversion ⢠Leverage risk PGEN's recent quarter shows a sharp profitability rebound and solid liquidity, but persistent cash burn, elevated leverage, and a very rich valuation keep the risk profile high.
Price Behavior
Key Price Behavior Insights: ⢠Higher-lows trend ⢠Sharp pullback ⢠Support test Support Level: $6.00 Resistance Level: $6.85-$7.23 PGEN has been in a short-term uptrend over the last month, but the sharp drop from $7.23 to $6.10 signals fading momentum and makes $6.00 support the key near-term line to watch.
Sentiment & News
Key News Insights: ⢠PAPZIMEOS ramp ⢠First profit ⢠Premium valuation Precigen's blowout Q2, driven by rapid PAPZIMEOS sales growth and its first quarterly profit, points to strong execution but also a valuation that may be getting ahead of itself.
AI Summary
PGEN has shifted from a speculative biotech to a one-product commercial rollout story, but the investment now hinges on PAPZIMEOS sustaining revenue growth and converting accounting profit into real cash flow amid high valuation and single-asset concentration risk.
Description
Precigen, Inc. is a U.S.-based biotechnology company that discovers and develops gene and cell therapies and related disease-modifying therapeutics. The company also supports regenerative medicine and reproductive technologies, including genetically engineered swine and embryo transfer services, and maintains a suite of platform technologies for gene delivery, regulated expression, non-viral integration and microbial delivery of therapeutic proteins. Precigen has a history of collaboration and licensing arrangements with multiple partners, was founded in 1998, and changed its name from Intrexon Corporation in January 2020; it is headquartered in Germantown, Maryland.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 21 | Aug 28 | PGEN | Precigen, Inc. | PAPZIMEOS Q2 revenue more than doubled to $53.1 million, EPS of $0.05 beat an expected loss, and FDA exclusivity runs through 2032. Shares gained about 34% over 21 sessions, with $7.44 the near-term breakout level. | Active | +0.0% |